

# Retrieve Conference Information

*Missed out on conferences this year? Find out what happened at the conference you couldn't attend.*

Benefit from comprehensive event coverage within *Integrity* and get the latest advances from more than 400 congresses each year. Use *Integrity* to get alerts on new citations from the latest edition of a particular conference relevant to you, and keep up-to-date with what's new in your area. **Example scenario:** You are a molecular biologist and want to see up-to-date information from a recent conference. A colleague has told you that material regarding the target you both are working on was presented at a conference that she had been unable to attend.

## Search for specific information from a conference:

**Advanced Search** | Session History | Clear Form | Start

**Reference**

Year (Congress) ▶ 2017 Index AND ▶

Source (Congress) ▶ "EORTC-NCI-AACR Symp Mol Targets Cancer Ther" Index AND ▶

Optional Value ▶ Index AND ▶

Make your selection directly from the list at right or enter a word or part of a word in the box below and click Lookup to display on the right a short list of search terms from which to make your selection. It is not necessary to use truncation indicators.

EORTC Lookup

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Select one or more terms from the list below and click OK to copy the term(s) to the Search Form.

AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther  
 ASCO-EORTC-NCI Annu Meet Markers Cancer  
 ASCO-NCI-EORTC Annu Meet Mol Markers Cancer  
**EORTC-NCI-AACR Symp Mol Targets Cancer Ther**  
 EORTC-NCI-ASCO Annu Meet Mol Markers Cancer  
 Meet EORTC-PAMM Group  
 NCI-EORTC Symp New Drugs Cancer Ther  
 Wint Meet EORTC-PAMM Group Max Delbruck Cent Mol Med  
 Winter Meet EORTC-PAMM Group

To find all references associated with a specific conference go to the **Literature** Knowledge Area.

### Tip:

- To view citations from the most recent meetings, go to the **Conferences** section at the bottom of the *Integrity* homepage.

Use the **Source** and **Year** fields in the Congress dropdown menu to set up a search. Enter 2017 in the **Year (Congress)** field.

**Advanced Search** | Session History | Clear Form | Start

**Reference**

Year (Congress) ▶ 2017 Index AND ▶

Source (Congress) ▶ "EORTC-NCI-AACR Symp Mol Targets Cancer Ther" Index AND ▶

Optional Value ▶ Index AND ▶

**Product** Structure Search

☐ Lead Compounds ☐ Under Active Development

Mechanism of Action ▶ "ERK2 Inhibitors" Index AND ▶

Optional Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

The **Index** associated with the **Congress Source** field can be used to find the specific term you need.

Searching for the "EORTC-NCI AACR Symposium on Molecular Targets and Cancer Therapeutics" can be done by entering EORTC in the **Lookup** box and clicking **Lookup**. You can select the specific conference from the list of options presented on the right. Click **OK** to copy the term into the search form.

This search will retrieve all the citations in *Integrity* from the 2017 edition of the chosen conference.

If you are interested in only the citations associated with products with a certain mechanism of action, this can be included in the search using the **Product** section. This again retrieves a results list with the relevant citations.

**Records Retrieved** 0 Thomson Reuters Drug News Records, 0 Prous References Records, and 4 other records

**Biomedical Literature List**

Query > Year = 2017 AND Source = "EORTC-NCI-AACR Symp Mol Targets Cancer Ther" AND Mechanism of Action =

**Munck, J.M.; Berdini, V.; Bevan, L.D.; et al.** Summary OpenURL Full Text  
 Characterization of a novel ERK1/2 inhibitor, which modulates the phosphorylation and catalytic activity of ERK1/2  
 29th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (October 26-30, Philadelphia) 2017, Abst B154

**RELATED INFORMATION** CLINICAL TRIALS EXPERIMENTAL PHARMACOLOGY EXPERIMENTAL MODELS

**Heightman, T.D.; Berdini, V.; Braithwaite, H.; et al.** Summary OpenURL Full Text  
 Fragment-based discovery of a highly potent, orally bioavailable ERK1/2 inhibitor that modulates the activity of ERK1/2  
 29th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (October 26-30, Philadelphia) 2017, Abst B161

**RELATED INFORMATION** CLINICAL TRIALS EXPERIMENTAL PHARMACOLOGY EXPERIMENTAL MODELS PHARMACOKINETICS & METABOLISM

**Flemington, V.; Simpson, I.; Davies, E.; et al.** OpenURL Full Text  
 Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor  
 29th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (October 26-30, Philadelphia) 2017, Abst B156

**Options**

- Save Query
- Keep Me Posted
- Export Center
- Integrity Reports
- Product List
- Display References with associated text
- All Related Information via Quick Search**
- Printer Friendly Format

**Reference**

29th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (October 26-30, Philadelphia) 2017, Abst B154

**Title**

Characterization of a novel ERK1/2 inhibitor, which modulates the phosphorylation and catalytic activity of ERK1/2

(980502)

Synthesis and optimization led to the discovery of a novel series of pERK modulating ERK1/2 inhibitors. The lead compound, compound [I], inhibited ERK1/2 catalytic activity with an IC<sub>50</sub> of 3 nM when evaluated in an ERK TRF kinase assay. The compound bound to the active site of ERK2, and in a screen of 465 kinases it proved to be highly selective for ERK1/2. In A375 (BRAF-mutant melanoma) and HCT116 (KRAS-mutant colorectal cancer) cell lines, [I] potently inhibited ERK activity with IC values of 7.2 and 5.2 nM, respectively. Additionally, the compound inhibited the proliferation of cell lines harboring a range of MAPK aberrations. In vivo, [I] was evaluated in A375 (BRAF-mutant melanoma) and Calu-6 (KRAS-mutant lung) tumor xenografts, demonstrating that once-daily oral administration of 50 mg/kg of this compound resulted in significant antitumor activity in both models. A single dose at 50 mg/kg inhibited ERK catalytic activity in KRAS-mutant lung tumor xenografts and conferred a decrease in the phosphorylation of ERK itself. These effects on ERK catalytic activity and phosphorylation were sustained for up to 24 hours.

**Tip:**

- Checkboxes can be used to select specific records which can then be further manipulated using **Options** such as **Export to Excel** or **Integrity Reports** that *Integrity* makes available for easy data management.

Where available, an **Integrity Summary** button will appear next to the reference citation. *Integrity* in-house specialists have analyzed the information and published a summary of the findings. Click the button to access this information in a separate pop-up window.

To see information related to the citations that can be found in the different Knowledge Areas of *Integrity* go to **All Related Information via Quick Search**, which is one of the data management **Options**. Link to **Drugs & Biologics** to view the drug records associated with these references.

You can explore *Integrity* reference citations to see more literature associated with your area of interest.

For example, in the **Literature Knowledge Area** use the **Product** section to search for references associated with products that have a mechanism of interest. You can specify to see all the citations that have been published this year.

Records Retrieved 7 in Drugs & Biologics Search Results Options								
Drugs & Biologics Search Results 1								
Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Mechanism of Action	Organization
355417*	Phase III	ARRY-142886 hydrogen sulfate ARRY-886 hydrogen sulfate AZD-6244 Hyd-Sulfate AZD-6244 hydrogen sulfate MK-5618 NSC-748727	Selumetinib sulfate (Prop INN; USAN)			Multiple Myeloma Therapy Sarcoma Therapy Non-Small Cell Lung Cancer Therapy Endocrine Cancer Therapy Neurological Genetic Disorders, Treatment of Neurologic Cancer Therapy Melanoma Therapy Gastric Cancer Therapy Breast Cancer Therapy Ovarian Cancer Therapy	Dual Specificity Mitogen-Activated Protein Kinase 2 (MAP2K2; MEK2) Inhibitors Signal Transduction Modulators Extracellular-Regulated	National Cancer Institute Array BioPharma (Originator) AstraZeneca University of Chicago Samsung Medical Center Merck & Co.

Advanced Search	Session History	Clear Form	Start
<b>Reference</b>			
Year	From 2017	Index	AND
Optional Value		Index	AND
Optional Value		Index	AND
<b>Product</b> Structure Search			
<input type="checkbox"/> Lead Compounds <input type="checkbox"/> Under Active Development			
Mechanism of Action	"ERK2 Inhibitors"	Index	AND
Optional Value		Index	AND
Optional Value		Index	AND

## Set up alerts for forthcoming conferences:

Advanced Search	Session History	Clear Form	Start
<b>Reference</b>			
Source (Congress)	"EORTC-NCI-AACR Symp Mol Targets Cancer Ther"	Index	AND
Year	From 2018	Index	AND
Optional Value		Index	AND

**Biomedical Literature Search Results**

Sorry, no results for this search. Perhaps you need to use a wildcard (\*).

Please check spelling and use of operators and wildcards.

Suggestion: You can consult the Browse Index feature to select terms or to see the appropriate format to use.

Back
Save Query

You can set up a **Save Query** alert to be notified when new citations from the latest edition of a particular conference are included in *Integrity*.

Set up a search for **Source (Congress)** [conference/congress of interest] and **Year = From 2018**. Your search will not retrieve results if the conference is in the future.

You will be given a **Save Query** option.

**Save Query**

To save your query, enter a Query Name and Description and click Save Query.

Use the Optional e-mail alert field to change the frequency of alerts: never, daily, weekly or monthly.

When new records are found by the query, you will receive notification by e-mail.

Query Name

Description

Optional e-mail alert

Email Address

You can add additional email addresses for this alert. Separate email addresses with a semi-colon (;)

Fill in the appropriate fields, select an alert frequency and save the alert. You will now be notified when new records that meet your search criteria enter *Integrity*.

---

**Tip:** For information about forthcoming conferences to be covered in Integrity, refer to the left-hand side of the advanced search form in the **Literature Knowledge Area**. The tabs contain information about recent **conferences** (left tab) and **forthcoming conferences** (right tab) covered by Integrity.

---